Skip to content
Study details
Enrolling now

A Study of JNJ-89402638 for Metastatic Colorectal Cancer

Janssen Research & Development, LLC
NCT IDNCT06663319ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

170

Study length

about 3.8 years

Ages

18+

Locations

5 sites in CO, FL, IN +2

What this study is about

This trial is testing a treatment called JNJ-89402638 in people with advanced colorectal cancer that cannot be surgically removed. The goal is to find the best dose of this medication and see if it's safe at that dose.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take JNJ-89402638

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVInjection / IV

How treatment is administered

Treatment Assignment
Standard assignment

Assignment is predetermined by the study protocol.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

bevacizumab

Drug routes

infusion

Endpoints

Primary: Part 1 and Part 2: Number of Participants with Adverse Events (AEs) by Severity, Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)

Secondary: Part 1 and Part 2: Area Under the Serum Concentration-time Curve (AUC) of JNJ-89402638, Part 1 and Part 2: Complete Response (CR), Part 1 and Part 2: Duration of Response (DOR), Part 1 and Part 2: Maximum Serum Concentration (Cmax) of JNJ-89402638, Part 1 and Part 2: Overall Response (OR), Part 1 and Part 2: Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-89402638

Body systems

Oncology